Nielsen KL et al. |
Biglycan deficiency interferes with ovariectomy-induced bone loss. |
2003 |
J. Bone Miner. Res. |
pmid:14672350
|
Amizuka N et al. |
Defective bone remodelling in osteoprotegerin-deficient mice. |
2003 |
J Electron Microsc (Tokyo) |
pmid:14756238
|
Kawana F and Sasaki T |
Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. |
2003 |
J Electron Microsc (Tokyo) |
pmid:14756239
|
Okuma K et al. |
Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. |
2003 |
J. Virol. |
pmid:12857926
|
Cheng X et al. |
The TNF receptor superfamily: role in immune inflammation and bone formation. |
2003 |
Immunol. Res. |
pmid:12857975
|
Shin MM et al. |
High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. |
2003 |
Exp. Mol. Med. |
pmid:12858015
|
Gehrke T et al. |
Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. |
2003 |
Scand. J. Rheumatol. |
pmid:14690142
|
Glossop JR et al. |
No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. |
2003 |
J. Rheumatol. |
pmid:12858434
|
Hampson G et al. |
Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. |
2003 |
Osteoporos Int |
pmid:12904840
|
Stolina M et al. |
Regulatory effects of osteoprotegerin on cellular and humoral immune responses. |
2003 |
Clin. Immunol. |
pmid:14697750
|
Misra M et al. |
Serum osteoprotegerin in adolescent girls with anorexia nervosa. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12915674
|
Lonergan M et al. |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12915677
|
Kapczuk K et al. |
[Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. |
2003 |
Ginekol. Pol. |
pmid:12916277
|
Liu JZ et al. |
[Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. |
2003 |
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi |
pmid:12916296
|
Bendre MS et al. |
Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. |
2003 |
Bone |
pmid:12919697
|
Tabb MM et al. |
Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. |
2003 |
J. Biol. Chem. |
pmid:12920130
|
Park HR et al. |
Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. |
2003 |
J. Korean Med. Sci. |
pmid:12923331
|
Naylor KE et al. |
Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:14602774
|
Paloneva J et al. |
DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. |
2003 |
J. Exp. Med. |
pmid:12925681
|
Fukushima H et al. |
Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. |
2003 |
Eur. J. Oral Sci. |
pmid:12887401
|
Ito R et al. |
Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. |
2003 |
Virchows Arch. |
pmid:12838418
|
Hayashi S et al. |
Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. |
2003 |
J. Immunol. |
pmid:14607912
|
Terpos E et al. |
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. |
2003 |
Int. J. Cancer |
pmid:12845688
|
Schett G et al. |
Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. |
2003 |
Arthritis Rheum. |
pmid:12847699
|
Gruber HE and Rude RK |
Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse. |
2003 |
Biotech Histochem |
pmid:14989640
|
Wagner TU et al. |
The teleost fish medaka (Oryzias latipes) as genetic model to study gravity dependent bone homeostasis in vivo. |
2003 |
Adv Space Res |
pmid:15000082
|
Nakamura M et al. |
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. |
2003 |
Endocrinology |
pmid:14500574
|
Zhang Z et al. |
Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. |
2003 |
J. Immunol. |
pmid:14500659
|
Ueno Y et al. |
In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. |
2003 |
J. Cell. Biochem. |
pmid:14505343
|
Kaneyama K et al. |
Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. |
2003 |
Int J Oral Maxillofac Surg |
pmid:14505625
|
Miyahira Y et al. |
Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. |
2003 |
J. Immunol. |
pmid:14662831
|
Seidlova-Wuttke D et al. |
Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. |
2003 |
Eur. J. Endocrinol. |
pmid:14514351
|
Hortobagyi GN |
Novel approaches to the management of bone metastases. |
2003 |
Semin. Oncol. |
pmid:14613037
|
Voskaridou E et al. |
Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. |
2003 |
Br. J. Haematol. |
pmid:14616979
|
Uemura H et al. |
Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. |
2003 |
Bone |
pmid:14623063
|
Novack DV |
TSH, the bone suppressing hormone. |
2003 |
Cell |
pmid:14567908
|
Abe E et al. |
TSH is a negative regulator of skeletal remodeling. |
2003 |
Cell |
pmid:14567913
|
Zhao ZM et al. |
[The preliminary study on in vitro differentiation of human umbilical cord blood cells into neural cells]. |
2003 |
Zhonghua Xue Ye Xue Za Zhi |
pmid:14575594
|
Boyan BD et al. |
Osteoblasts generate an osteogenic microenvironment when grown on surfaces with rough microtopographies. |
2003 |
Eur Cell Mater |
pmid:14577052
|
Zhang J et al. |
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. |
2003 |
Cancer Res. |
pmid:14633717
|
Grigorie D et al. |
Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. |
2003 |
Rom J Intern Med |
pmid:15526523
|
Kanatani M et al. |
Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. |
2003 |
J. Cell. Physiol. |
pmid:12767054
|
Nagata N et al. |
Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. |
2003 |
Bone |
pmid:14555278
|
Grimaud E et al. |
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. |
2003 |
Am. J. Pathol. |
pmid:14578201
|
Bord S et al. |
The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. |
2003 |
Bone |
pmid:12633785
|
Coen G et al. |
Serum leptin in dialysis renal osteodystrophy. |
2003 |
Am. J. Kidney Dis. |
pmid:14582047
|
Garber K |
Why it hurts: researchers seek mechanisms of cancer pain. |
2003 |
J. Natl. Cancer Inst. |
pmid:12783923
|
Chagraoui H et al. |
Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. |
2003 |
Exp. Hematol. |
pmid:14585373
|
Liu B et al. |
Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. |
2003 |
J. Oral Pathol. Med. |
pmid:12787044
|
Eaton CL and Coleman RE |
Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. |
2003 |
Cancer Treat. Rev. |
pmid:12787713
|
Fahrleitner-Pammer A et al. |
Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. |
2003 |
Wien. Klin. Wochenschr. |
pmid:12793029
|
Dovio A et al. |
Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. |
2003 |
Clin. Cancer Res. |
pmid:12796409
|
Flick LM et al. |
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. |
2003 |
J. Orthop. Res. |
pmid:12798068
|
Khapli SM et al. |
IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. |
2003 |
J. Immunol. |
pmid:12816992
|
Kawase Y et al. |
Bone malformations in interleukin-18 transgenic mice. |
2003 |
J. Bone Miner. Res. |
pmid:12817749
|
Kikuchi T et al. |
Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. |
2003 |
J. Dent. Res. |
pmid:12821717
|
D'Elia HF et al. |
Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. |
2003 |
Arthritis Res. Ther. |
pmid:12823855
|
Knudsen ST et al. |
Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. |
2003 |
Eur. J. Endocrinol. |
pmid:12824864
|
Fox SW et al. |
The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. |
2003 |
J. Immunol. |
pmid:12646633
|
Varsani H et al. |
Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). |
2003 |
Rheumatology (Oxford) |
pmid:12649407
|
Wise GE et al. |
Regulation of osteoprotegerin gene expression in dental follicle cells. |
2003 |
J. Dent. Res. |
pmid:12651935
|
Schoppet M et al. |
Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. |
2003 |
Circulation |
pmid:12654623
|
Nimmanapalli R and Bhalla K |
Targets in apoptosis signaling: promise of selective anticancer therapy. |
2003 |
Methods Mol. Biol. |
pmid:12777745
|
Zheng B et al. |
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. |
2003 |
Blood |
pmid:12689928
|
Moreno JL et al. |
IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. |
2003 |
Blood |
pmid:12689929
|
Dovio A et al. |
Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. |
2003 |
J. Endocrinol. |
pmid:12697042
|
Nakano M et al. |
Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. |
2003 |
Oral Dis |
pmid:12657033
|
Ra JS et al. |
Osteoprotegerin inhibits proliferation of myeloid progenitor cells. |
2003 |
J. Hematother. Stem Cell Res. |
pmid:12662434
|
Szalay F et al. |
High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. |
2003 |
J. Hepatol. |
pmid:12663228
|
Okada Y et al. |
Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. |
2003 |
J. Biol. Chem. |
pmid:12665515
|
Bell NH |
RANK ligand and the regulation of skeletal remodeling. |
2003 |
J. Clin. Invest. |
pmid:12697730
|
Eghbali-Fatourechi G et al. |
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. |
2003 |
J. Clin. Invest. |
pmid:12697741
|
Enomoto H et al. |
Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. |
2003 |
J. Biol. Chem. |
pmid:12697767
|
Nakashima T et al. |
RANKL and RANK as novel therapeutic targets for arthritis. |
2003 |
Curr Opin Rheumatol |
pmid:12707582
|
Johnson-Pais TL et al. |
Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. |
2003 |
Int. J. Cancer |
pmid:12673693
|
Zaidi M et al. |
Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. |
2003 |
J. Bone Miner. Res. |
pmid:12674320
|
Tanaka S et al. |
Signal transduction pathways regulating osteoclast differentiation and function. |
2003 |
J. Bone Miner. Metab. |
pmid:12720046
|
Valleala H et al. |
Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. |
2003 |
Eur. J. Endocrinol. |
pmid:12720535
|
Yonou H et al. |
Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. |
2003 |
Cancer Res. |
pmid:12727825
|
Capparelli C et al. |
Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. |
2003 |
J. Bone Miner. Res. |
pmid:12733724
|
Wong T et al. |
Therapeutic implications for interferon-alpha in arthritis: a pilot study. |
2003 |
J. Rheumatol. |
pmid:12734885
|
Lipton A |
Bisphosphonates and metastatic breast carcinoma. |
2003 |
Cancer |
pmid:12548585
|
Demers LM |
Bone markers in the management of patients with skeletal metastases. |
2003 |
Cancer |
pmid:12548589
|
Body JJ et al. |
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. |
2003 |
Cancer |
pmid:12548591
|
Xing L et al. |
Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. |
2003 |
J. Bone Miner. Res. |
pmid:12568403
|
Cao J et al. |
Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. |
2003 |
J. Bone Miner. Res. |
pmid:12568404
|
Johnson-Pais TL et al. |
Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. |
2003 |
J. Bone Miner. Res. |
pmid:12568416
|
Clohisy JC et al. |
RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. |
2003 |
J. Orthop. Res. |
pmid:12568950
|
Fahrleitner A et al. |
Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. |
2003 |
Bone |
pmid:12584041
|
Lanzi R et al. |
GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. |
2003 |
Eur. J. Endocrinol. |
pmid:12590637
|
Shipman CM and Croucher PI |
Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. |
2003 |
Cancer Res. |
pmid:12615702
|
Hamzei M et al. |
Osteoclast stimulating and differentiating factors in human cholesteatoma. |
2003 |
Laryngoscope |
pmid:12616193
|
Siggelkow H et al. |
Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. |
2003 |
J. Bone Miner. Res. |
pmid:12619938
|
Toraldo G et al. |
IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. |
2003 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:12490655
|
Rude RK et al. |
Magnesium deficiency: effect on bone and mineral metabolism in the mouse. |
2003 |
Calcif. Tissue Int. |
pmid:12370796
|
Takayanagi H |
[Signaling mechanism in the regulation of osteoclast differentiation by the immune system]. |
2003 |
Seikagaku |
pmid:14748148
|
Chen X et al. |
Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. |
2003 |
J. Nutr. Biochem. |
pmid:12873716
|
Bridgham JT and Johnson AL |
Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin. |
2003 |
Biochem. Biophys. Res. Commun. |
pmid:12878204
|
Riggs BL et al. |
Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. |
2003 |
Osteoporos Int |
pmid:12879223
|
Sasaki T |
Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. |
2003 |
Microsc. Res. Tech. |
pmid:12879416
|